Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Biochemicals

The licenses signed on 15 July 2009, provide Enigma full access under patents owned or licensed by RMS and its affiliates to practice HybProbe real-time PCR chemistry and melt analysis and will allow Enigma to commercialize HybProbe PCR tests for human and veterinary in vitro diagnostics on a worldwide basis. The two licenses with RMS complement Enigma's existing patent portfolio as well as intellectual property licensed by Celera Diagnostics for real-time PCR thermal cyclers.

Financial terms were not disclosed.

Enigma Diagnostics Limited specialises in developing next generation rapid molecular diagnostic instrument platforms for decentralised and point-of-care settings.

Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded Research. It also has licenses from Applied Biosystems and Celera Diagnostics for commercialization of real-time PCR instruments. Enigma's R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.

SOURCE Enigma Diagnostics Limited

CONTACT: UK Contact, Enigma Diagnostics, Deborah Cordingley,
+44-1980-590131, deborah.cordingley@enigmadiagnostics.com; or US Contact,
Media, Andrew Mielach, amielach@rlcinc.com, or Investors, Cecelia Heer,
cheer@rlcinc.com, both of Richard Lewis Communications, Inc.,
+1-212-827-0020, for Enigma Diagnostics Limited

Web site: http://www.enigmadiagnostics.com/

Back to news